Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -17.09%317.42K | -44.26%182.92K | 33.63%275.15K | -13.09%94.98K | 8.89%45.66K | 197.13%382.83K | 743.34%328.14K | 899.53%205.9K | 243.72%109.29K | 11.71%41.94K |
| Selling and administrative expenses | 34.49%46.8K | 714.66%31.99K | -19.39%36.82K | 293.59%15.54K | 276.13%6.48K | -27.03%34.8K | -145.50%-5.21K | 588.57%45.67K | -70.71%3.95K | -94.08%1.72K |
| -General and administrative expense | 34.49%46.8K | 714.66%31.99K | -19.39%36.82K | 293.59%15.54K | 276.13%6.48K | -27.03%34.8K | -145.50%-5.21K | 588.57%45.67K | -70.71%3.95K | -94.08%1.72K |
| Other operating expenses | -22.24%270.62K | -54.72%150.92K | 48.74%238.33K | -24.58%79.45K | -2.56%39.19K | 328.86%348.03K | 1,113.50%333.35K | 1,047.21%160.23K | 474.96%105.34K | 375.84%40.21K |
| Operating profit | 17.09%-317.42K | 44.26%-182.92K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.34%-328.14K | -899.53%-205.9K | -243.72%-109.29K | -11.71%-41.94K |
| Net non-operating interest income (expenses) | -10.78K | 0 | ||||||||
| Non-operating interest income | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Non-operating interest expense | --10.78K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other net income (expenses) | 50.39K | |||||||||
| Special income (charges) | --50.39K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less:Other special charges | ---50.39K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Income before tax | 27.43%-277.81K | 56.33%-143.31K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.34%-328.14K | -899.53%-205.9K | -243.72%-109.29K | -11.71%-41.94K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 27.43%-277.81K | 56.33%-143.31K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.34%-328.14K | -899.53%-205.9K | -243.72%-109.29K | -11.71%-41.94K |
| Net income continuous operations | 27.43%-277.81K | 56.33%-143.31K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.34%-328.14K | -899.53%-205.9K | -243.72%-109.29K | -11.71%-41.94K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 27.43%-277.81K | 56.33%-143.31K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.36%-328.14K | -899.54%-205.91K | -243.72%-109.29K | -11.71%-41.93K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 27.43%-277.81K | 56.33%-143.31K | -33.63%-275.15K | 13.09%-94.98K | -8.89%-45.66K | -197.13%-382.83K | -743.36%-328.14K | -899.54%-205.91K | -243.72%-109.29K | -11.71%-41.93K |
| Diluted earnings per share | 40.00%-0.003 | 65.91%-0.0015 | -50.00%-0.003 | 16.67%-0.001 | 16.67%-0.0005 | -150.00%-0.005 | -340.00%-0.0044 | -900.00%-0.002 | -300.00%-0.0012 | -20.00%-0.0006 |
| Basic earnings per share | 40.00%-0.003 | 65.91%-0.0015 | -50.00%-0.003 | 16.67%-0.001 | 16.67%-0.0005 | -150.00%-0.005 | -340.00%-0.0044 | -900.00%-0.002 | -300.00%-0.0012 | -20.00%-0.0006 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.